Get the Stockscreener App
40.90
4.37%
-1.87
Merus N V stock is traded at $40.90, with a volume of 556.15K.
It is down -4.37% in the last 24 hours and up +3.39% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$42.77
Open:
$43
24h Volume:
556.15K
Relative Volume:
0.77
Market Cap:
$3.06B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-10.35
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
-7.45%
1M Performance:
+3.39%
6M Performance:
-24.95%
1Y Performance:
-9.35%
1-Day Range:
$40.90
$44.22
1-Week Range:
$37.92
$45.12
52-Week Range:
$33.19
$61.61
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
40.90 | 3.06B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Piper Sandler | Overweight |
| Feb-07-25 | Initiated | Wells Fargo | Overweight |
| Nov-21-24 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Mar-28-24 | Initiated | Truist | Buy |
| Mar-04-24 | Reiterated | Needham | Buy |
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités - GlobeNewswire Inc.
Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités - GlobeNewswire
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline - MSN
Wells Fargo Maintains Overweight Rating on MRUS but Lowers Price Target | MRUS Stock News - GuruFocus
Merus to Present at BofA Securities 2025 Health Care Conference - The Manila Times
Wells Fargo Adjusts Price Target for Merus (MRUS), Maintains Overweight Rating | MRUS Stock News - GuruFocus
Merus NV reports results for the quarter ended March 31Earnings Summary - TradingView
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (MRUS) Merus NV Posts Q1 Revenue $26.5M - marketscreener.com
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update - GlobeNewswire
Financial Health Check: Examining Merus N.V (MRUS)’s Key Ratios - DWinneX
(MRUS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Was Merus N.V (MRUS)’s session last reading good? - uspostnews.com
Merus (NASDAQ:MRUS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Q1 Earnings Forecast for Merus Issued By Leerink Partnrs - Defense World
Investor Network: Merus N.V. to Host Earnings Call - ACCESS Newswire
FY2027 Earnings Forecast for Merus Issued By Leerink Partnrs - Defense World
Merus (NASDAQ:MRUS) Position Lifted by Geode Capital Management LLC - Defense World
William Blair Reiterates Outperform Rating for Merus (NASDAQ:MRUS) - Defense World
Market Watch Highlights: Merus N.V (MRUS) Ends on an Upturn Note at 45.28 - DWinneX
Russell Investments Group Ltd. Decreases Stock Holdings in Merus (NASDAQ:MRUS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Merus N.V (MRUS) Is Worth Accumulating At Current Levels - Stocksregister
Daily Progress: Merus N.V (MRUS) Drop -3.19, Closing at 41.83 - DWinneX
MRUS Stock Sees Decline of Approximately -3.22% in Last Five Days - knoxdaily.com
Merus N.V’s Banking’s 100-Day Moving Average at 43.17: Will the Stock Break Through? - investchronicle.com
A stock that deserves closer examination: Merus N.V (MRUS) - uspostnews.com
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting - The Manila Times
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting | MRUS Stock News - GuruFocus
Merus N.V. Announces Interim Clinical Data for Petosemtamab with Pembrolizumab in PD-L1+ r/m HNSCC to be Presented at 2025 ASCO® Annual Meeting - Nasdaq
Breakthrough Cancer Drug Outperforms Standard Treatment: Phase 2 Trial Shows Superior Survival Rates - Stock Titan
ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals | Libero Quotidiano.it - Libero Quotidiano
Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now? - Yahoo
10 Best High Short Interest Stocks to Buy Now - Insider Monkey
Merus N.V (NASDAQ: MRUS): Getting A Free Pass? - stocksregister.com
Merus’ (MRUS) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Raymond James Financial Inc. Invests $347,000 in Merus (NASDAQ:MRUS) - Defense World
Merus: Riding The Bispecific Wave In Oncology (NASDAQ:MRUS) - Seeking Alpha
KLP Kapitalforvaltning AS Purchases New Holdings in Merus (NASDAQ:MRUS) - Defense World
Merus stock touches 52-week low at $37.76 amid market challenges By Investing.com - Investing.com South Africa
Merus stock touches 52-week low at $37.76 amid market challenges - Investing.com Australia
HighTower Advisors LLC Has $337,000 Position in Merus (NASDAQ:MRUS) - Defense World
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
How To Trade (MRUS) - news.stocktradersdaily.com
Leading Biotech Merus Showcases Next-Gen Antibody Technologies at Major Healthcare Conference - Stock Titan
Merus (NASDAQ:MRUS) Shares Purchased by Teacher Retirement System of Texas - Defense World
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merus N V Stock (MRUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shuman Harry | VP Controller, PAO |
Mar 21 '25 |
Sale |
48.50 |
4,000 |
193,990 |
11,002 |
| Shuman Harry | VP Controller, PAO |
Jan 01 '25 |
Option Exercise |
0.00 |
5,000 |
0 |
12,002 |
| Lundberg Sven Ante | President, CEO & PEO |
Feb 13 '25 |
Option Exercise |
24.43 |
16,372 |
399,968 |
40,601 |
| Shuman Harry | VP Controller, PAO |
Aug 21 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Aug 20 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Option Exercise |
17.94 |
10,000 |
179,400 |
10,000 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Sale |
60.00 |
10,000 |
600,000 |
0 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Option Exercise |
24.36 |
62,000 |
1,510,280 |
62,000 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Sale |
56.52 |
62,000 |
3,504,178 |
0 |
| Shuman Harry | VP Controller, PAO |
Jun 12 '24 |
Sale |
57.84 |
7,300 |
422,232 |
7,002 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):